L-amphetamine improves memory in MS patients with objective memory impairment

Area of Science:

• Neuroscience
• Clinical Neurology
• Psychopharmacology

Background:

• Memory impairment is a common and debilitating symptom in multiple sclerosis (MS).
• Currently, no approved pharmaceutical treatments specifically target memory deficits in MS patients.
• This study addresses the unmet need for effective memory-enhancing therapies in MS.

Purpose of the Study:

• To evaluate the efficacy of l-amphetamine in improving auditory/verbal and visual/spatial memory.
• To compare the effects of l-amphetamine versus placebo in MS patients.
• To determine if treatment effects differ between MS patients with and without baseline memory impairment.

Main Methods:

• Re-analysis of a randomized, double-blind, placebo-controlled clinical trial.
• Participants received either 30 mg of l-amphetamine or placebo for four weeks.
• Auditory/verbal (CVLT-II) and visual/spatial (BVMT-R) memory were assessed at baseline and follow-up in patients categorized by baseline memory status (intact vs. impaired).

Main Results:

• A significant interaction effect was observed for both memory types, indicating l-amphetamine's superior efficacy over placebo.
• The memory improvement associated with l-amphetamine was statistically significant.
• This beneficial effect was exclusive to MS patients who exhibited memory impairment at the study's commencement.

Conclusions:

• L-amphetamine demonstrated substantial memory improvement in MS patients with baseline memory deficits.
• Memory-impaired MS patients treated with l-amphetamine experienced approximately 48.5% improvement, compared to only 1.0% with placebo.
• L-amphetamine represents a promising therapeutic option for addressing memory dysfunction in multiple sclerosis.